News
Hormone therapy heart-safe for under 60s with menopause symptoms

Hormone therapy is safe for treating menopause symptoms such as hot flushes and night sweats in women aged 50–59, but should not be started after 70 due to cardiovascular risks, research shows.
The study analysed 20 years of data from over 27,000 women aged 50–79 with moderate to severe menopausal symptoms who received either treatment or placebo.
Women who began therapy between 50 and 59 showed no higher risk of heart disease compared with placebo.
In contrast, those over 70 faced substantially increased risk of atherosclerotic cardiovascular disease – a build-up of plaque in arteries that can lead to heart attacks and strokes.
Co-author JoAnn Manson is chief of the division of preventive medicine at Brigham and Women’s Hospital.
She said: “This paper has a very important message for clinicians and women considering HT use: HT is appropriate and has a favourable benefit: risk profile for treating hot flushes among women below age 60, but it’s important to avoid starting treatment after age 70 among women with hot flushes.
“Our findings support current HT guidelines but help to clarify that risk varies strongly by age.”
Researchers at Brigham and Women’s Hospital examined data from the Women’s Health Initiative trials, addressing long-standing fears about hormone therapy and heart safety.
The study is the first to look closely at links between hot flushes, hormone treatment and cardiovascular risk across different age groups.
Many women have avoided hormone therapy – used to ease hot flushes, night sweats and other symptoms – since earlier studies raised concerns about heart disease.
The new analysis showed clear age-related differences. Women starting treatment in their 50s had no added heart risks, while those beginning after 70 faced substantially higher danger.
Manson, a founding member of the Mass General Brigham healthcare system, is one of the principal investigators of the Women’s Health Initiative.
The findings offer guidance for treatment decisions during menopause, when falling oestrogen levels cause symptoms that can disrupt daily life. Hormone therapy replaces these hormones to reduce symptoms.
The heart safety profile differs sharply by age.
For women in their 50s, therapy carries no extra cardiovascular risk while easing symptoms. But beginning after 70 brings substantial risks, particularly of atherosclerotic disease.
The results support current clinical guidelines while adding clearer, age-specific evidence to help women and doctors make informed choices based on individual risk.
The distinction between age groups is key for treatment planning, offering reassurance to younger women considering therapy while warning against late initiation in older age.
Menopause
Perimenopause misinformation ‘putting women at risk’
Insight
Early PET scan could chemo response in aggressive breast cancer – study
News
Femtech World reveals startup of the year shortlist

We are excited unveil the three finalists competing for one of the Femtech World Awards’ most coveted honours: the Startup of the Year Award, sponsored by Future Fertility.
This award celebrates an early-stage company making a bold impact in women’s health through innovation, vision and execution.
The winner will be announced at our virtual ceremony on 19 June, with the decision made by a representative from category sponsor Future Fertility.
Congratulations to the shortlist and thank you to everyone who entered or nominated.
Startup of the Year Shortlist

Hello Inside is the first women’s health AI company to turn daily metabolic signals into outcomes women feel and healthcare systems reimburse.
Women’s health has long been under-researched, and current AI benchmarks fail on women’s health questions roughly sixty percent of the time.
Hello Inside built the architecture to close that gap.
Across four years and 12,000+ validated metabolic profiles, three in four women improve at least one symptom within ninety days.
They lose four kilograms in three months, moving from overweight into the healthy range. In a clinical study with Alisa Vitti’s Flo Living, 91.9 per cent reduced PMS burden within sixty days.


U-Ploid is an early-stage biotechnology company tackling one of the most fundamental challenges in fertility care: the sharp, age-related decline in egg quality that limits outcomes across IVF and egg freezing.
While much of the field focuses on improving assessment and selection, U-Ploid is developing a first-in-class therapeutic approach designed to improve egg quality itself by addressing the biological causes of age-related chromosomal errors.
Supported by strong preclinical evidence and now advancing into human studies, U-Ploid combines scientific rigour, regulatory discipline and long-term vision to help redefine what is possible in fertility care.
Entrepreneur4 weeks agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
Insight4 weeks agoWhy the UK’s fertility rate keeps falling – and what it means if you’re trying now
Wellness4 weeks agoWomen’s HealthX unveils Northwell Health, Corewell Health, Biogen & more to headline Chronic Disease stage
Motherhood3 weeks agoWhat Maternal Mental Health Month reveals about where postpartum support actually breaks down
Fertility4 weeks agoToxins and climate harms having ‘alarming’ effect on fertility, research warns
News3 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Adolescent health3 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Fertility4 weeks agoResearcher explores weight loss jab impact on PCOS
















